Shortage concerns as TGA suspends all brands of ranitidine

Regulator says the quality is unacceptable

The TGA is suspending all remaining brands of ranitidine from the therapeutic register for six months, prompting concerns that other heartburn medicines will go into short supply.


Four months after eight ranitidine products were recalled as a result of contamination with a possible carcinogen, the regulator says it has decided to suspend the remaining products from the therapeutic register (ARTG) because their quality is unacceptable.